FDA recommits to drug safety (Miami Herald)
Responding to scathing criticism, the Food and Drug Administration offered a blueprint Tuesday to revamp the way it monitors prescription-drug safety.
FDA recommits to prescription drug safety (Miami Herald)
Responding to scathing criticism, the Food and Drug Administration offered a blueprint Tuesday to revamp the way it monitors prescription-drug safety.
FDA vows to overhaul drug safety system (St. Louis Post-Dispatch)
WASHINGTON — The Food and Drug Administration pledged Tuesday to undertake a major overhaul of its drug safety system, just months after a blue-ribbon panel of medical and legal experts concluded that the agency’s priorities were skewed toward approving new medications without enough follow-up of risky side effects.
FDA announces overhaul of drug safety program (St. Petersburg Times)
It adopts some recommendations from a panel. WASHINGTON - The Food and Drug Administration on Tuesday said it is making a range of changes in how it operates to prevent the kind of drug safety controversies that have dogged the agency in recent years.
FDA details safety plan, including monitoring (The Star-Ledger)
WASHINGTON — The Food and Drug Administration yesterday outlined a series of new safety initiatives in response to harsh criticism that it has failed to adequately protect the public from problem drugs like the painkiller Vioxx.
FDA vows to overhaul drug safety system (Los Angeles Times)
The Food and Drug Administration pledged Tuesday to undertake a major overhaul of its drug safety system, just months after a blue ribbon panel of medical and legal experts concluded that the agency’s priorities were skewed toward approving new medications without enough follow-up of risky side effects.
Changes will ensure drug safety, FDA says (Los Angeles Times)
Approved medications will be better tracked in a bid to regain the trust of patients and doctors. WASHINGTON — The Food and Drug Administration pledged Tuesday to make major changes in the nation’s drug safety system, responding to a blue-ribbon panel that last fall found the agency’s priorities skewed toward approving new medications without adequate follow-up to identify rare but risky side …
FDA to Monitor Post-Market Drug Safety (HealthCentral.com)
TUESDAY, Jan. 30 (HealthDay News) — In an apparent attempt to address growing criticism of its operations, the U.S. Food and Drug Administration unveiled a set of initiatives Tuesday that are intended to bolster the country’s health safety net.
FDA proposes ‘report cards’ on the safety of new drugs (USA Today)
As part of a pilot program, the Food and Drug Administration will issue drug “report cards” that would detail unexpected side effects that emerge only after a drug has been approved. The reports also would include follow-up studies and details about how the drugs are being used.
FDA plans to boost safety with newsletters, drug profiles (USA Today)
Food and Drug Administration officials unveiled a variety of initiatives Tuesday to improve drug safety and expand information to the public about the medicines they take.